SMARCA4-deficient dedifferentiated ovarian carcinoma with rapid progression during adjuvant platinum-based chemotherapy: a case report and implications for molecular-driven treatment strategies
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F25%3A00082857" target="_blank" >RIV/65269705:_____/25:00082857 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/25:00142650
Result on the web
<a href="https://journals.sagepub.com/doi/full/10.1177/17588359251376858" target="_blank" >https://journals.sagepub.com/doi/full/10.1177/17588359251376858</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1177/17588359251376858" target="_blank" >10.1177/17588359251376858</a>
Alternative languages
Result language
angličtina
Original language name
SMARCA4-deficient dedifferentiated ovarian carcinoma with rapid progression during adjuvant platinum-based chemotherapy: a case report and implications for molecular-driven treatment strategies
Original language description
Dedifferentiated ovarian carcinomas (DDOC) are rare and aggressive malignancies characterized by a mixture of differentiated and undifferentiated tumor components, often associated with poor prognosis. This case report describes a 55-year-old woman initially diagnosed with early-stage high-grade endometrioid ovarian carcinoma who experienced rapid disease progression during adjuvant platinum-based chemotherapy, culminating in death within 4 months. Retrospective molecular analyses revealed pathogenic variants in the SMARCA4 gene, leading to a revised diagnosis of DDOC. The tumor exhibited resistance to conventional chemotherapy, highlighting the challenges associated with managing this aggressive tumor subtype. In our case, molecular profiling identified two potentially targetable alterations: biallelic SMARCA4 loss and a pathogenic PIK3CA mutation, both of which may inform future therapeutic strategies. This case underscores the importance of integrating molecular diagnostics into routine practice for accurate classification and highlights the urgent need for personalized treatment strategies, including targeted and immunotherapy options, for this formidable tumor subtype.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Therapeutic Advances in Medical Oncology
ISSN
1758-8340
e-ISSN
1758-8359
Volume of the periodical
17
Issue of the periodical within the volume
2025
Country of publishing house
GB - UNITED KINGDOM
Number of pages
8
Pages from-to
17588359251376858
UT code for WoS article
001595874600001
EID of the result in the Scopus database
2-s2.0-105019083125